Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AFFY's Cash to Debt is ranked higher than
95% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. AFFY: No Debt )
AFFY' s 10-Year Cash to Debt Range
Min: 6.71   Max: 13531.29
Current: No Debt

6.71
13531.29
F-Score: 2
Z-Score: -117.59
M-Score: 34.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1099.05
AFFY's Operating margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. AFFY: -1099.05 )
AFFY' s 10-Year Operating margin (%) Range
Min: -45958.11   Max: -12.84
Current: -1099.05

-45958.11
-12.84
Net-margin (%) -1053.62
AFFY's Net-margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. AFFY: -1053.62 )
AFFY' s 10-Year Net-margin (%) Range
Min: -44021.62   Max: -12.51
Current: -1053.62

-44021.62
-12.51
ROA (%) -193.79
AFFY's ROA (%) is ranked lower than
51% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. AFFY: -193.79 )
AFFY' s 10-Year ROA (%) Range
Min: -193.79   Max: -10.71
Current: -193.79

-193.79
-10.71
Revenue Growth (%) -79.40
AFFY's Revenue Growth (%) is ranked higher than
54% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. AFFY: -79.40 )
AFFY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 187
Current: -79.4

0
187
EBITDA Growth (%) -7.50
AFFY's EBITDA Growth (%) is ranked higher than
76% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. AFFY: -7.50 )
AFFY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 25
Current: -7.5

0
25
EPS Growth (%) -11.90
AFFY's EPS Growth (%) is ranked higher than
75% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. AFFY: -11.90 )
AFFY' s 10-Year EPS Growth (%) Range
Min: -65.5   Max: 17.4
Current: -11.9

-65.5
17.4
» AFFY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

AFFY Guru Trades in

AFFY Guru Trades in

Q1 2013

AFFY Guru Trades in Q1 2013

Jim Simons 1,027,867 sh (New)
Paul Tudor Jones 305,400 sh (New)
Steven Cohen Sold Out
» More
Q2 2013

AFFY Guru Trades in Q2 2013

Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-03-31 Sold Out 0.06%$6.53 - $14.31 $ 0.11-99%0
George Soros 2011-12-31 Add 800.9%0.05%$4.24 - $7.8 $ 0.11-98%200000
George Soros 2011-09-30 Reduce -83.4%0.01%$4.04 - $7.78 $ 0.11-98%22200
George Soros 2011-06-30 New Buy0.01%$5.85 - $7.16 $ 0.11-98%133717
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 0.40
AFFY's P/E(ttm) is ranked higher than
100% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: 0.40 )
AFFY' s 10-Year P/E(ttm) Range
Min: 0   Max: 6.4
Current: 0.4

0
6.4
P/S 7.20
AFFY's P/S is ranked higher than
59% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. AFFY: 7.20 )
AFFY' s 10-Year P/S Range
Min: 0.13   Max: 11.68
Current: 7.2

0.13
11.68
EV-to-EBIT -0.11
AFFY's EV-to-EBIT is ranked lower than
53% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AFFY: -0.11 )
AFFY' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -0.11

Current Ratio 0.62
AFFY's Current Ratio is ranked lower than
51% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. AFFY: 0.62 )
AFFY' s 10-Year Current Ratio Range
Min: 0.62   Max: 21.42
Current: 0.62

0.62
21.42
Quick Ratio 0.62
AFFY's Quick Ratio is ranked higher than
50% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AFFY: 0.62 )
AFFY' s 10-Year Quick Ratio Range
Min: 0.62   Max: 21.42
Current: 0.62

0.62
21.42

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 462.90
AFFY's Earnings Yield (Greenblatt) is ranked higher than
90% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. AFFY: 462.90 )
AFFY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 21110.7
Current: 462.9

0
21110.7
Forward Rate of Return (Yacktman) -2518.33
AFFY's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. AFFY: -2518.33 )
AFFY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -2518.33

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:A5Y.Germany
Affymax, Inc. incorporated in Delaware in July 2001. It is a biopharmaceutical company discovering, developing and delivering innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses. Its clinical trials include: Phase 3b Conversion Study (DIAMOND trial) and Phase 2 Study in Dialysis and Non-dialysis Patients with PRCA. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for AFFY

Headlines

Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
comment on AFFY Mar 15 2013 
comment on AFFY Mar 02 2013 
Weekly CFO Sells Highlight: PII, ASNA, FIO, VVUS, AFFY Jul 23 2012 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares May 19 2010 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares May 13 2010 
AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares Feb 26 2010 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares Sep 30 2009 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares Sep 02 2009 
AFFYMAX, INC. Reports Operating Results (10-Q) Aug 05 2009 

More From Other Websites
AFFYMAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 18 2014
AFFYMAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2014
Affymax board announces decision to dissolve company Jun 24 2014
Affymax Board Announces Decision to Dissolve the Company Jun 24 2014
AFFYMAX INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements... Jun 13 2014
Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and... Jun 13 2014
Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and... Jun 13 2014
AFFYMAX INC Files SEC form 8-K, Other Events May 14 2014
AFFYMAX INC Financials May 14 2014
AFFYMAX INC Files SEC form 10-Q, Quarterly Report May 06 2014
AFFYMAX INC Files SEC form 10-K, Annual Report Mar 31 2014
AFFYMAX INC Files SEC form 10-Q, Quarterly Report Nov 05 2013
New Data Show Omontys At Least 4x Worse Than Reported: Now 22 Suspected Deaths Oct 14 2013
Just Like Omontys.com, Affymax Is Likely To Disappear Sep 10 2013
Don't Believe In Affymax - The Stock Is Probably Worthless Aug 29 2013
Affymax: Getting The Facts Straight Aug 29 2013
Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen Aug 28 2013
Affymax: Putting The Pieces Together Aug 24 2013
AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Aug 20 2013
AFFYMAX INC Files SEC form 8-K, Other Events Aug 16 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide